Eli Lilly's $7.8B deal and FDA boost growth
Watch: Track early sales of Foundayo and Centessa integration progress to gauge new revenue streams and pipeline expansion.
Full analysis
Eli Lilly hit $829 billion market cap, fueled by 44.7% revenue growth to $65.18 billion and 94.9% net income rise in 2025. FDA approved Foundayo, a GLP-1 oral weight loss pill launching April 6. Lilly acquired Centessa for $7.8 billion to expand brain disorder treatments, partnering with NVIDIA for AI in drug development. 2026 guidance forecasts $80-$83 billion revenue, with incretin drugs making up 56% of sales.
The combination of blockbuster diabetes drugs, strategic acquisitions, and AI partnerships accelerates Lilly's transition into a biotech powerhouse with sustained revenue and innovation growth.
Get alerted when LLY changes direction
Evidence
7 older signals
Get alerted when LLY changes direction.